Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 15Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Peripheral Blood Stem Cell Transplantation 39fludarabine phosphate 37Cyclophosphamide 33Mycophenolic Acid 28Whole-Body Irradiation 24Cyclosporine 24Tacrolimus 22Radiotherapy 19Methotrexate 18Busulfan 18Antilymphocyte Serum 17Flow Cytometry 14Filgrastim 14Etoposide 14Vorinostat 11Bortezomib 11Bexarotene 11mogamulizumab 10Methylprednisolone 10Lenalidomide 10pembrolizumab 9Rituximab 9Melphalan 9Gemcitabine 9Brentuximab Vedotin 9romidepsin 8Therapeutics 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Methoxsalen 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mycosis Fungoides × trastuzumab biosimilar HLX02 × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡